• Return to Headlines

Relatively High EBITDA Growth Detected in Shares of Incyte Corp in the Biotechnology Industry (INCY, EXEL, LGND, MDXG, VRTX)

By Nick Russo

Below are the three companies in the Biotechnology industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Incyte Corp ranks highest with a EBITDA growth of 317.0%. Exelixis Inc is next with a EBITDA growth of 266.9%. Ligand Pharm ranks third highest with a EBITDA growth of 172.0%.

Mimedx Group Inc follows with a EBITDA growth of 167.2%, and Vertex Pharm rounds out the top five with a EBITDA growth of 142.5%.

SmarTrend recommended that subscribers consider buying shares of Vertex Pharm on January 6th, 2017 as our technology indicated a new Uptrend was in progress when shares hit $78.63. Since that recommendation, shares of Vertex Pharm have risen 95.6%. We continue to monitor Vertex Pharm for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: highest ebitda growth incyte corp exelixis inc ligand pharm mimedx group inc vertex pharm

Ticker(s): INCY EXEL LGND MDXG VRTX